178 results
8-K
EX-99.1
RZLT
Rezolute Inc
25 Apr 24
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
5:23pm
Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which
8-K
EX-99.1
RZLT
Rezolute Inc
11 Mar 24
Regulation FD Disclosure
5:03pm
Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements
8-K
EX-99.1
RZLT
Rezolute Inc
13 Feb 24
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
4:10pm
such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation
8-K
EX-99.1
RZLT
Rezolute Inc
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act
8-K
EX-99.2
xdgewf64yw qmnd
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
8-K
EX-99.2
xagkp8fxq0jo1
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
8-K
EX-99.1
7m5vx 2am9z98k05d
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
8-K
EX-99.1
1iez qmzwn
13 Nov 23
Rezolute Reports First Quarter Fiscal 2024 Results
4:13pm
8-K
EX-99
h6e0zlp8
18 Oct 23
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
4:30pm
8-K
EX-99
yz2pxf5vlg99
13 Oct 23
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
4:47pm
8-K
EX-99.1
msgji p8h
14 Sep 23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
ibakyu7xxkqc3qq
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
EX-99.1
6lhxr7oiwcw71i
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm